The Exchange has received the disclosure under Regulation 29(2) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011 for Virupaksha Organics Ltd
Price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
Oxygenta Pharmaceutical Ltd (BSE Scrip Code: 524636) has forwarded to BSE a disclosure received from Virupaksha Organics Ltd, its parent company, under Regulation 29(2) of the SEBI Substantial Acquisition of Shares & Takeovers Regulations, 2011. Regulation 29(2) is triggered when an existing significant shareholder crosses the 2% creeping acquisition or disposal threshold in a financial year. The covering letter does not contain the actual transaction details — the substantive enclosure (share count, price, pre/post shareholding) is not included in the provided text. The letter is dated 13 February 2026 and signed by Kumkum Bajaj, Company Secretary.
The filing itself is procedural — it is only the forwarding of a required disclosure. Without the enclosed details (direction of trade, size, and resulting shareholding), investors cannot yet judge whether this is a stake build-up, a partial sale, or a routine compliance trigger. Watch for Virupaksha Organics' updated shareholding pattern for actual impact on promoter holding.